Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & Novartis

14 shared events · Importance 4 · Last updated Aug 14, 2026

Importance
4
Shared Events
14
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
79
International
United States: The United States is receiving significant investment from Swiss companies, which will boost its economy and create jobs, though it also imposed new tariffs related to forced labor.
Novartis: Novartis is a key investor, announcing two U.S. projects: a biomedical research center in San Diego and a cancer-drug production facility in Texas.
Jun 07, 2026 · 7 articles
69
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Novartis: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
55
Regulatory
United States: The United States is noted as a jurisdiction where Novartis lost a bid to block a generic version of Sacubitril/valsartan, representing a contrasting legal outcome.
Novartis: Novartis is the patent holder and beneficiary of the court ruling, which protects its blockbuster drug Sacubitril/valsartan from generic competition in the UK, supporting its revenue and market position.
Aug 13, 2026 · 6 articles
39
Regulatory
United States: The U.S. FDA granted approval, impacting the domestic IgAN patient population of about 160,000.
Novartis: Novartis' Fabhalta and Vanrafia are among the competitors to TRUTAKNA in IgAN.
Jul 07, 2026 · 6 articles
30
Business
United States: The US is a key market for PentixaFor, with an expanded patient pool due to new screening guidelines.
Novartis: Novartis reported strong Pluvicto sales growth, indicating a booming radiopharma market that could benefit PentixaFor's launch.
Jul 15, 2026 · 10 articles
20
Domestic
United States: Prospects of a peace deal between Iran>>> and the United States>>> influenced investor sentiment, contributing to the positive mood in the Switzerland>>> market.
Novartis: Novartis>>> shed 0.3%-0.7% in one session but moved up by 1.85% in another, showing mixed performance in the Switzerland>>> market.
May 21, 2026 · 8 articles
20
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
Novartis: Novartis' Leqvio is another competitor in the PCSK9 inhibitor market. Scribe's progress may affect Novartis's competitive position.
Jul 06, 2026 · 25 articles
10
Business
United States: The United States is the primary market for Lantheus' products and the regulatory jurisdiction for the deal, with potential antitrust review.
Novartis: Novartis is mentioned as the maker of Pluvicto, a competitor to a Lantheus-Eli Lilly therapeutic that was abandoned.
Aug 03, 2026 · 7 articles
10
Business
United States: Country where Palsonify is approved and where most patients reside.
Novartis: Competitor in acromegaly market.
Jul 06, 2026 · 34 articles
0
Regulatory
Novartis: Novartis is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
0
Business
Novartis: Novartis settled a lawsuit with the estate of Henrietta Lacks over the unauthorized use of her cells, which were used to develop various medical advancements. This settlement resolves a significant legal and ethical challenge for Novartis.
Feb 26, 2026 · 7 articles
0
International
Novartis: Novartis employed Jason Thomas, a pharmaceutical researcher who was found dead after disappearing, adding a pharmaceutical link to the broader pattern of mysterious deaths.
Apr 11, 2026 · 6 articles
0
Business
Novartis: Novartis announced the expansion of its community health programs to address gaps in heart disease and cancer care globally, which could positively impact its public image and long-term market position.
Apr 09, 2026 · 7 articles
0
Tech
Jun 12, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States and Novartis interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.